Ellis C N, Kang S, Vinik A I, Grekin R C, Cunningham W J, Voorhees J J
Arch Dermatol. 1987 Apr;123(4):471-5.
Since lipemia is commonly induced by retinoid therapy, we investigated the effects of etretinate administration on glucose metabolism by obtaining five-hour oral glucose tolerance tests in 23 patients before and after 20 weeks of etretinate therapy for psoriasis. Compared with pretreatment values, peak and aggregate levels for serum glucose and aggregate levels for serum insulin were significantly lower during therapy. The changes were not associated with obesity, weight loss during treatment, or pretherapy glucose tolerance or insulin secretion level. Of 11 patients with impaired or diabetic glucose tolerance prior to therapy, eight patients had improved glucose tolerance after 20 weeks of etretinate treatment. Despite inducing hypertriglyceridemia in most patients, etretinate therapy is associated with a reduction in glucose levels in response to a glucose load.
由于血脂异常通常由维甲酸治疗引起，我们通过对23例银屑病患者在依曲替酯治疗20周前后进行5小时口服葡萄糖耐量试验，研究了依曲替酯给药对葡萄糖代谢的影响。与治疗前的值相比，治疗期间血清葡萄糖的峰值和总量以及血清胰岛素的总量显著降低。这些变化与肥胖、治疗期间体重减轻或治疗前葡萄糖耐量或胰岛素分泌水平无关。在治疗前葡萄糖耐量受损或患有糖尿病的11例患者中，8例患者在依曲替酯治疗20周后葡萄糖耐量得到改善。尽管依曲替酯治疗在大多数患者中诱发了高甘油三酯血症，但它与葡萄糖负荷后血糖水平的降低有关。
